Further pages

• Latest News and Archive
• Yearbook and Newsletters

EJCMO: Clinical Debate Series: Emerging Evidence in Treating Patients with Refractory Chronic Lymphocytic Leukaemia (CLL)

with Drs Peter Hillmen, Stephan Stilgenbauer, William Wierda and Susan O'Brien

Patients with refractory chronic lymphocytic leukaemia (CLL) have an unfavourable prognosis and continue to pose a daunting challenge for the haematologist. In particular, we are now seeing refractoriness not just with fludarabine but also fludarabine-combinations (e.g. cyclophosphomide, rituximab and alemtuzumab). But there are emerging treatment options for these patients beyond enrolling them in clinical trials. Drs Peter Hillman, Stephan Stilgenbauer, William Wierda and Susan O'Brien discuss and debate emerging evidence in treating patients with refractory CLL in a 4 part video series.

http://www.ejcmo.tv/clinical-debate-series-emerging-evidence-in-treating-patients-with-refractory-cll-introduction/

http://www.ejcmo.tv/clinical-evidence-for-safety-and-efficacy-of-ofatumuab-in-refractory-cll

http://www.ejcmo.tv/managing-adverse-events-associated-with-ofatumumab

http://www.ejcmo.tv/preventing-infusion-related-adverse-drug-reactions

Please visit the latest online EJCMO newsletter here for more debate, interviews and podcasts.

26 Apr 2012